| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net cash provided by investing activities | 21,465 | 9,607 |
| Proceeds from the sale of common stock | 19,838 | - |
| Cash paid for issuance costs of stock | 1,531 | - |
| Proceeds from sale of series a convertible preferred stock | 7,862 | - |
| Cash paid for extinguishment-Two Thousand Twenty Six Senior Unsecured Convertible Notes | 125,000 | - |
| Cash paid for extinguishment-Notes Payable | 25,000 | - |
| Proceeds from notes payable issuance-Two Thousand Thirty One Senior Unsecured Convertible Notes | 33,250 | - |
| Cash paid for notes payable debt issuance cost-Two Thousand Thirty One Senior Unsecured Convertible Notes | 1,386 | - |
| Proceeds from notes payable issuance-Notes Payable | 108,787 | - |
| Cash paid for notes payable debt issuance cost-Notes Payable | 3,406 | - |
| Proceeds from purchases under the employee stock purchase plan | 587 | 587 |
| Receipts for stock issued under the equity incentive plan | 207 | 258 |
| Net cash provided by financing activities | 14,208 | 845 |
| Net increase (decrease) in cash and cash equivalents | 17,266 | -9,286 |
| Cash and cash equivalents at beginning of period | 25,802 | - |
| Cash and cash equivalents at end of period | 43,068 | - |
HERON THERAPEUTICS, INC. DE (HRTX)
HERON THERAPEUTICS, INC. DE (HRTX)